To inhibit, or to degrade? That was our question. In the case of #AURKA in neuroblastoma, we chose targeted degradation using #PROTACs. Read more about it in our latest paper! https://t.co/CRFsDIsGrM
Congratulations to Muhammad Rishfi @kdurinck@crighent@ugent for winning the EMBO reports poster prize at #EMBOcellSignaling with his poster:
Targeted protein degradation of aurora kinase a using protacs as a precision medicine approach in neuroblastoma.
What a great week it's been at #EMBOcellSignaling in #Cavtat, Croatia. Many inspiring talks at such an amazing venue. Very happy & grateful as well to have been awarded for my poster🙏🏼. Thanks to the organizers for the wonderful experience🙌🏼 @SpelemanLab@FWOVlaanderen@crighent
Excited to share our latest publication "RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition" https://t.co/sHEkGH1RAP @crighent
Biomedical scientist @MuhammadRishfi has been awarded the ‘Prijs Vrienden van de Bibliomedische Bibliotheek’ for the best interdisciplinary thesis with highest clinical relevance at @ugent_fge. So well deserved Affy! Proud promoter!
Who? Despite COVID obstacles Affy @MuhammadRishfi did brilliant collaborative work with Sarah Naessens, @elfridedebaere, Jan Gettemans @GulliverBiomed, Frauke Coppieters, Olivier Zwaenepoel, Steve Lefever. To be continued.